AN OPEN LABEL, RANDOMIZED, SINGLE CENTER, TWO-STAGE, TWO-PERIOD CROSS-OVER STUDY TO INVESTIGATE THE BIOEQUIVALENCE OF TOCILIZUMAB IN HEALTHY SUBJECTS FOLLOWING SUBCUTANEOUS ADMINISTRATION OF CURRENT COMMERCIAL PRODUCT AND NEW PRODUCT

Trial Profile

AN OPEN LABEL, RANDOMIZED, SINGLE CENTER, TWO-STAGE, TWO-PERIOD CROSS-OVER STUDY TO INVESTIGATE THE BIOEQUIVALENCE OF TOCILIZUMAB IN HEALTHY SUBJECTS FOLLOWING SUBCUTANEOUS ADMINISTRATION OF CURRENT COMMERCIAL PRODUCT AND NEW PRODUCT

Completed
Phase of Trial: Phase I

Latest Information Update: 25 May 2017

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Amyotrophic lateral sclerosis; Chronic lymphocytic leukaemia; Dermatomyositis; Giant cell arteritis; Giant lymph node hyperplasia; Juvenile rheumatoid arthritis; Polymyalgia rheumatica; Polymyositis; Rheumatoid arthritis; Systemic scleroderma; Vasculitis
  • Focus Pharmacokinetics
  • Sponsors Chugai Pharmaceutical; Roche
  • Most Recent Events

    • 22 May 2017 Status changed from active, no longer recruiting to completed.
    • 16 Jun 2016 New trial record
    • 10 Mar 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top